RealFeedApp beta

Novo and Lilly present early longevity data

Novo Nordisk and Eli Lilly presented data showing reduced mortality and improved physical function in a cohort of 19,117 participants from the SELECT trial.

Field
ageing and longevity
What they did
Novo Nordisk and Eli Lilly presented preliminary data suggesting that GLP-1 drugs (including semaglutide) may reduce mortality and improve physical function, which models predict could lead to increased life expectancy.
Why it matters
This information will help determine how effectively these drugs can extend healthy life and could serve as a basis for future clinical trials.
#glp-1#semaglutide#longevity#select trial

Read the original →